Cargando…

Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study

BACKGROUND: Whether paricalcitol (PCT) reduces proteinuria in the presence of intensified inhibition of Renin-Angiotensin-System (RAS) is poorly studied. We evaluated the antiproteinuric effect of PCT in non-dialysis chronic kidney disease (CKD) patients with proteinuria greater than 0.5 g/24 h pers...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Nicola, Luca, Conte, Giuseppe, Russo, Domenico, Gorini, Antonio, Minutolo, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511164/ https://www.ncbi.nlm.nih.gov/pubmed/23167771 http://dx.doi.org/10.1186/1471-2369-13-150

Ejemplares similares

Paricalcitol as an Antiproteinuric Agent Can Result in the Deterioration of Renal and Heart Function in a Patient with Fabry Disease
por: Keber, Tajda, et al.
Publicado: (2017)

Diminished antiproteinuric effect of the angiotensin receptor blocker losartan during high potassium intake in patients with CKD
por: Wouda, Rosa D, et al.
Publicado: (2021)

The effect of a ketogenic diet on weight loss in CKD: a randomized controlled trial in obese stage G1–3a CKD patients
por: Zoccali, Carmine, et al.
Publicado: (2023)

Epidemiology of CKD Regression in Patients under Nephrology Care
por: Borrelli, Silvio, et al.
Publicado: (2015)

Thiazide diuretics are back in CKD: the case of chlorthalidone
por: Minutolo, Roberto, et al.
Publicado: (2022)

Moderate Antiproteinuric Effect of Add-On Aldosterone Blockade with Eplerenone in Non-Diabetic Chronic Kidney Disease. A Randomized Cross-Over Study
por: Boesby, Lene, et al.
Publicado: (2011)

Interplay of Vitamin D, Erythropoiesis, and the Renin-Angiotensin System
por: Santoro, Domenico, et al.
Publicado: (2015)

Role of angiotensin converting enzyme and angiotensinogen gene polymorphisms in angiotensin converting enzyme inhibitor-mediated antiproteinuric action in type 2 diabetic nephropathy patients
por: Aggarwal, Neerja, et al.
Publicado: (2017)

Renin-Angiotensin System Inhibitors in Advanced CKD: a #NephJC Editorial on STOP-ACEi
por: Thanabalasingam, Susan, et al.
Publicado: (2023)

Comparison of spironolactone and trichlormethiazide as add‐on therapy to renin–angiotensin blockade for reduction of albuminuria in diabetic patients
por: Hase, Michiyo, et al.
Publicado: (2013)

Ferric Carboxymatose in Non-Hemodialysis CKD Patients: A Longitudinal Cohort Study
por: Minutolo, Roberto, et al.
Publicado: (2021)

Is the Antiproteinuric Effect of Cyclosporine A Independent of Its Immunosuppressive Function in T Cells?
por: Zhang, Bin, et al.
Publicado: (2012)

Prescription of renin‐angiotensin‐aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care
por: Pecoits‐Filho, Roberto, et al.
Publicado: (2019)

Current Management of Hyperkalemia in Non-Dialysis CKD: Longitudinal Study of Patients Receiving Stable Nephrology Care
por: Borrelli, Silvio, et al.
Publicado: (2021)

New-onset anemia and associated risk of ESKD and death in non-dialysis CKD patients: a multicohort observational study
por: Minutolo, Roberto, et al.
Publicado: (2022)

Alisol B 23-acetate attenuates CKD progression by regulating the renin–angiotensin system and gut–kidney axis
por: Chen, Hua, et al.
Publicado: (2020)

Urinary angiotensinogen as a surrogate marker predicting the antiproteinuric effects of angiotensin receptor blockers in patients with overt proteinuria: a multicenter prospective study
por: Jeon, Junseok, et al.
Publicado: (2020)

Treatment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin
por: Chung, Sungjin, et al.
Publicado: (2017)

Evaluation of antiproteinuric and hepato-renal protective activities of propolis in paracetamol toxicity in rats
por: El Menyiy, Nawal, et al.
Publicado: (2018)

Role of Paricalcitol in Modulating the Immune Response in Patients with Renal Disease
por: Lucisano, Silvia, et al.
Publicado: (2015)

What’s new in the renin-angiotensin system?: What’s new in the renin-angiotensin system?
por: Smith, A. I., et al.
Publicado: (2004)

Impact of Baseline Clinical Variables on SGLT2i’s Antiproteinuric Effect in Diabetic Kidney Disease
por: Capelli, Irene, et al.
Publicado: (2023)

Vitamin D Analogues and Coronary Calcification in CKD Stages 3 and 4: A Randomized Controlled Trial of Calcitriol Versus Paricalcitol
por: Anis, Karim H., et al.
Publicado: (2020)

Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade
por: Perez-Gomez, Maria Vanessa, et al.
Publicado: (2015)

Correction: Treatment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin
por: Chung, Sungjin, et al.
Publicado: (2018)

Effect of systemic arterial hypertension and use of antiproteinuric drug in induction therapy for lupus nephritis
por: Matta, Eduardo Grecco, et al.
Publicado: (2020)

Prognosis and determinants of serum PTH changes over time in 1-5 CKD stage patients followed in tertiary care
por: Borrelli, Silvio, et al.
Publicado: (2018)

The Renin-Angiotensin System Textbook
por: Cumming, Allan D
Publicado: (1994)

Brain renin angiotensin in disease
por: Phillips, M. Ian, et al.
Publicado: (2008)

Effects and Safety of Linagliptin as an Add-on Therapy in Advanced-Stage Diabetic Nephropathy Patients Taking Renin–Angiotensin–Aldosterone System Blockers
por: Ueda, Yuichiro, et al.
Publicado: (2016)

Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial
por: Larsen, Thomas, et al.
Publicado: (2013)

Amiloride as an Alternate Adjuvant Antiproteinuric Agent in Fabry Disease: The Potential Roles of Plasmin and uPAR
por: Trimarchi, H., et al.
Publicado: (2014)

Role of the eNOS-NO System in Regulating the Antiproteinuric Effects of VEGF Receptor 2 Inhibition in Diabetes
por: Advani, Andrew, et al.
Publicado: (2013)

Antiproteinuric and Hyperkalemic Mechanisms Activated by Dual Versus Single Blockade of the RAS in Renovascular Hypertensive Rats
por: Corrêa, José Wilson N., et al.
Publicado: (2021)

The role of renin angiotensin system inhibition in kidney repair
por: van der Meer, Irene M, et al.
Publicado: (2010)

Do Genetic Variants of the Renin-Angiotensin System Predict Blood Pressure Response to Renin-Angiotensin System–Blocking Drugs? A Systematic Review of Pharmacogenomics in the Renin-Angiotensin System
por: Konoshita, Tadashi
Publicado: (2011)

Effects of Vitamin D on the Renin–Angiotensin System and Acute Childhood Pneumonia
por: Zovi, Andrea, et al.
Publicado: (2022)

Epidemiology of low-proteinuric chronic kidney disease in renal clinics
por: De Nicola, Luca, et al.
Publicado: (2017)

The renin–angiotensin system and diabetes: An update
por: Ribeiro-Oliveira, Antônio, et al.
Publicado: (2008)

ANGIOTENSIN AND RENIN IN RAT AND DOG BRAIN
por: Fischer-Ferraro, Catalina, et al.
Publicado: (1971)

Cannot write session to /tmp/vufind_sessions/sess_fuqlfjup4f4aed80jsf49eig39